878805-25-5

Basic information

• Product Name: 3-cyclopropylpyridin-2-aMine
• Synonyms: 3-cyclopropylpyridin-2-aMine
• CAS NO: 878805-25-5
• Molecular Formula: C8H10N2
• Molecular Weight: 134.1784
• Mol File: 878805-25-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-cyclopropylpyridin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-cyclopropylpyridin-2-aMine(878805-25-5)
• EPA Substance Registry System: 3-cyclopropylpyridin-2-aMine(878805-25-5)

Safety Data

• Hazardous Substances Data: 878805-25-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-cyclopropylpyridin-2-amine is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique structure and reactivity. Its presence in the molecular framework can contribute to the development of new drugs with specific therapeutic properties.
Used in Drug Development:
3-cyclopropylpyridin-2-amine is used as a potential candidate for drug development because of its demonstrated biological activity. Its ability to interact with biological targets makes it a promising starting point for the creation of new therapeutic agents.
Used in the Treatment of Certain Diseases and Medical Conditions:
3-cyclopropylpyridin-2-amine has been studied for its potential use in treating specific diseases and medical conditions. Its application in this context is based on its capacity to modulate biological processes that are implicated in the pathophysiology of these conditions.
Used in Organic Chemistry Research:
3-cyclopropylpyridin-2-amine is utilized in organic chemistry research to explore new synthetic pathways and to understand the reactivity of cyclopropyl-pyridine systems. This can lead to the discovery of novel organic compounds with potential applications in various fields.

Upstream product

• 13534-99-1 2-Amino-3-bromopyridine 
• 1065010-87-8 potassium cyclopropyltrifluoroborate 
• 411235-57-9 cyclopropylboronic acid 
• 39620-04-7 2-amino-3-chloropyridine 
• 878805-23-3 3-cyclopropylpyridine-2-carboxylic acid 

Downstream Products

• 1335059-09-0 5-bromo-3-cyclopropylpyridin-2-amine 
• 1620575-00-9 3-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

Provided herein are Heterocyclic compounds of formula (I): and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.

KRAS G12C INHIBITORS AND METHODS OF USING THE SAME

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Synthesis of bromocyclopropylpyridines via the Sandmeyer reaction

The reactions of 2-amino-5-cyclopropylpyridine with organic nitrites in the presence of copper(II) halides in various organic solvents were investigated. Optimal reaction conditions for the Sandmeyer reaction were developed and successfully applied to the synthesis of useful building blocks, bromo and chlorocyclopropylpyridines. Aminocyclopropylpyridines were synthesized in high yields from the corresponding aminobromopyridines under standard Suzuki coupling conditions.

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.